Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
FY 2025 (Ending March 31,2026) First Quarter Financial Results Reference Data
CONSOLIDATED FINANCIAL REPORT [IFRS] for the Three-Month Period Ended June 30, 2025
Revenue of LEQEMBI (Preliminary Basis)
Eisai Obtains Favorable Decision in Patent Infringement Litigation Related to Lenvatinib in the U.S.
Notification Regarding Partial Amendment to the Articles of Incorporation
FY 2024 (Ended March 31,2025) Full Year Financial Results Reference Data
CONSOLIDATED FINANCIAL REPORT [IFRS] for Fiscal 2024 (Year Ended March 31, 2025)
Notice Concerning Results of Tender Offer for Share Certificates, etc., of EcoNaviSta Inc. (Securities Code: 5585)
REVENUE OF LEQEMBI (PRELIMINARY BASIS)
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
Notice Concerning Commencement of Tender Offer for Share Certificates, etc., of EcoNaviSta Inc. (Securities Code: 5585)
Notification Regarding Changes in Representative Corporate Officers
Eisai Announces Appointments of Corporate Officers
Notice of Nominees for Directors
FY 2024 (Ending March 31, 2025) Third Quarter Financial Results Reference Data
CONSOLIDATED FINANCIAL REPORT [IFRS] for the Nine-Month Period Ended December 31, 2024
FDA Approves LEQEMBI(lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
FDA Accepts LEQEMBI(lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Eisai Announces Completion of Cancellation of Treasury Shares